NASDAQ:ECYT Endocyte (ECYT) Stock Price, News & Analysis → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) Free ECYT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$2.81▼$24.00VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Endocyte alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Endocyte Stock (NASDAQ:ECYT)Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.Read More Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> ECYT Stock News HeadlinesFebruary 16, 2024 | investing.comTelix Pharmaceuticals Ltd (TLX)January 3, 2024 | fool.com.au'The most exciting company in Australia': The ASX stock up 179% in 6 monthsMay 17, 2023 | thestreet.comThe Endocyte Bear Thesis: Why March Will be a Bad MonthJanuary 5, 2023 | thestreet.comWhy Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading TodaySeptember 20, 2022 | finance.yahoo.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo FinanceJune 6, 2022 | globenewswire.comPurdue University impacting lives: successfully delivering innovations to the public - GlobeNewswireMay 23, 2022 | globenewswire.comGlobal Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswireMay 20, 2022 | benzinga.comCortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - BenzingaMay 20, 2022 | streetinsider.comCortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.comMay 3, 2022 | nasdaq.comNovartis Is Looking for Deals. Are These 3 Biotechs on Its List? - NasdaqApril 25, 2022 | seekingalpha.comClovis: Shifting Toward Nuclear Medicine - Seeking AlphaApril 14, 2022 | globenewswire.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswireJanuary 31, 2022 | globenewswire.comNon-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comGlobal Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo FinanceDecember 19, 2021 | proactiveinvestors.com.auRadiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors AustraliaNovember 2, 2021 | finance.yahoo.comFusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo FinanceNovember 2, 2021 | streetinsider.comFusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.comSeptember 20, 2021 | streetinsider.comMirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.comAugust 16, 2021 | afr.comTelix Pharma is on the cusp of first US FDA approval - The Australian Financial ReviewSee More Headlines Receive ECYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2018Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ECYT CUSIP29269A10 CIK1235007 Webwww.endocyte.com Phone765-463-7175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,060,000.00 Net Margins-32,296.09% Pretax MarginN/A Return on Equity-21.19% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80 Sales & Book Value Annual Sales$70,000.00 Price / Sales28,133.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book12.06Miscellaneous Outstanding Shares82,090,000Free FloatN/AMarket Cap$1.97 billion OptionableOptionable Beta-0.01 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Michael A. Sherman (Age 52)CEO, Pres & Director Mr. Michael T. Andriole (Age 45)Chief Financial Officer Dr. Alison A. Armour (Age 54)Chief Medical Officer Dr. Christopher P. Leamon (Age 52)VP of R&D Dr. Philip S. Low (Age 70)Co-Founder, Chief Science Officer & Director Key CompetitorsJazz PharmaceuticalsNASDAQ:JAZZPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXView All Competitors ECYT Stock Analysis - Frequently Asked Questions How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative trailing twelve-month return on equity of 21.19% and a negative net margin of 32,296.09%. What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO). This page (NASDAQ:ECYT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endocyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.